IC-14 is under clinical development by Implicit Bioscience and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect IC-14’s likelihood of approval (LoA) and phase transition for Amyotrophic Lateral Sclerosis took place on 15 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their IC-14 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
IC-14 is under development for the treatment of Coronavirus disease 2019 (COVID-19), motor neurone disease (amyotrophic lateral sclerosis or ALS), and acute respiratory distress syndrome. It is a recombinant chimeric monoclonal antibody. It acts by targeting CD14, an essential component of the innate inflammatory response to bacterial infection. The drug candidate is administered through intravenous route. It was under development for the treatment of acute lung injury, community-acquired pneumonia, dengue fever and sepsis toxic shock.
Implicit Bioscience overview
Implicit Bioscience is a biotechnology company that develops drugs in the field of immunoneurology and therapies for life-threatening diseases. Implicit Bioscience is headquartered in Woolloongabba, Queensland, Australia.
Quick View IC-14 LOA Data
|Highest Development Stage|